A Study of Facilitators and Barriers to Improve Acute Kidney Injury in Children Through Mobile Health Intervention
Launched by DUKE UNIVERSITY · May 21, 2020
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on improving care for children with Acute Kidney Injury (AKI), a common condition that can lead to serious health problems if not managed properly. The study aims to understand what helps or hinders better care for these patients through the use of mobile health tools, which could include apps or text messages to support families and healthcare providers.
To take part in this study, children aged 1 to 18 years who have been diagnosed with AKI while in the hospital may be eligible. However, children who are legally blind or deaf, have significant cognitive impairments, do not speak English, or are older than 18 years cannot participate. Those who join the study can expect to help researchers learn more about how to enhance the care experience for kids with AKI and potentially contribute to better health outcomes for future patients. The trial is currently looking for participants, and your involvement could make a difference!
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • age 1 to 18 years
- • patients with diagnosis of AKI while hospitalized
- Exclusion Criteria:
- • legal blindness of deafness
- • cognitive impairment that limits ability to consent
- • non-English speaking
- • patient age greater than age 18 years, 11 months
About Duke University
Duke University, a leading academic and research institution located in Durham, North Carolina, is renowned for its commitment to advancing healthcare through innovative clinical research. With a strong emphasis on interdisciplinary collaboration, Duke conducts a wide array of clinical trials aimed at developing cutting-edge therapies and improving patient outcomes across various medical fields. The university's Clinical Research Institute provides comprehensive support for trial design, implementation, and regulatory compliance, ensuring that all research adheres to the highest ethical and scientific standards. Duke’s dedication to translating research findings into effective clinical practices underscores its role as a pivotal contributor to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Durham, North Carolina, United States
Patients applied
Trial Officials
Clarissa J Diamantidis, MD
Principal Investigator
Duke University
Rasheed Gbadegesin, MD
Principal Investigator
Duke University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials